Clindata Pharmaceutical and Biotechnology (Beijing) Co., Ltd., founded in Beijing, China in 2019, is the first innovative CRO focusing on the innovative strategy and design of innovative drugs for anti-tumor and other major diseases.Providing full-process services from IND to NDA, especially with extensive experience in the design and strategy of anti-tumor clinical trials, medical / clinical pharmacology, data management, and statistical analysis.Our business involves chemical drugs, biological products and cell therapy, and has in-depth research on pediatrics, rare diseases and bridging tests.

In the past few years, the Clindata  team has completed dozens of INDs applications and clinical trials of new class 1 anti-tumour drugs, including biological drugs and chemical drugs.At the same time, we focus on the development of clinical trial plans, and provide strategic design to help customers achieve clinical trials with the minimum sample size and the minimum time cost.Focusing on innovative drug design, especially anti-tumor clinical trials phase I, II, III, using Bayesian design method to help drug development, can achieve China and the United States.